Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine (MENHIBRIX)
Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine is an FDA-licensed reference biologic from GlaxoSmithKline Biologicals. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2012
Reference approved
Reference product
MENHIBRIX Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine
GlaxoSmithKline Biologicals
- Approved
- Jun 14, 2012
- Marketing
- Disc
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine, in chronological order.
Reference approval
Approval date of the reference Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine product.
14 yr 2 mo ago
Frequently asked questions
Are there biosimilars approved for Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine (MENHIBRIX)?
No 351(k) biosimilars or interchangeable biosimilars referencing Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.